Skip to main content
Premium Trial:

Request an Annual Quote

Christopher Moreau, Jim Charlton

Premium
Christopher Moreau was appointed president and CEO of Miraculins this week, replacing Jim Charlton who stepped down. Charlton remains a member of Miraculin’s board and will continue to provide guidance to the company, it said in a statement.
 
Moreau had served as vice president of business development since joining the company in March 2006. Before that he was president of Advansis Capital, a privately held Canadian financial services firm. The company did not disclose Moreau’s new salary, but said that it has granted him 130,000 stock options at an excise price of CA$.53 per share.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.